SLDB
NASDAQ · Biotechnology
Solid Biosciences Inc
$6.64
+0.36 (+5.73%)
Open$6.47
Previous Close$6.28
Day High$6.69
Day Low$6.37
52W High$11.45
52W Low$3.79
Volume—
Avg Volume1.11M
Market Cap716.80M
P/E Ratio—
EPS$-1.91
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+64.2% upside
Current
$6.64
$6.64
Target
$10.90
$10.90
$9.47
$10.90 avg
$14.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 294.33M | 265.12M | 296.42M |
| Net Income | 32.12M | 33.11M | 29.81M |
| Profit Margin | 10.9% | 12.5% | 10.1% |
| EBITDA | 56.98M | 46.74M | 49.34M |
| Free Cash Flow | 40.15M | 38.44M | 35.75M |
| Rev Growth | +16.9% | -8.0% | -9.5% |
| Debt/Equity | 0.34 | 0.27 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |